The Kennedy vaccine panel has reportedly postponed its vote on hepatitis B coverage, with the decision also impacting a previously scheduled vote on another vaccine’s coverage. The panel, which is responsible for evaluating the inclusion of vaccines in the national healthcare plan, had anticipated a vote on the hepatitis B vaccine’s coverage. However, the delay suggests that the panel is still deliberating on the issue, possibly due to concerns over the vaccine’s efficacy, cost, or other administrative issues. The panel also revisited a Thursday vote related to coverage for a different vaccine, indicating a broader review of vaccine coverage protocols.